Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 56565P103 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Pivotal bioVenture Partners Fund II, L.P.
13G
|
5.5% |
8/20/2026
Event 8/13/2026
|
|
| Nan Fung Group Holdings Limited | 5.5% | ||
| NF Investment Holdings Limited | 5.5% | ||
| Nan Fung Life Sciences Holdings Limited | 2.4% | ||
| NFLS Platform Holdings Limited | 1.3% | ||
| Pivotal Life Sciences Holdings Limited | 1.2% | ||
| Pivotal Partners Ltd | 1.2% | ||
| Pivotal bioVenture Partners Fund II G.P. Ltd | 1.2% | ||
| Pivotal bioVenture Partners Fund II, L.P. | 1.2% | ||
| NFLS Beta Limited | 1.3% | ||
| Permwell Management Limited | 3.1% | ||
|
Catalyst4, Inc.
13D/A
Amendment 2
|
49.9% |
8/18/2026
Event 8/14/2026
|
|
| Catalyst4, Inc. | 49.9% | ||
| Robert Brown | 49.9% | ||
| Ekemini Riley | 49.9% | ||
| Mark Vorsatz | 49.9% | ||
|
Catalyst4, Inc.
13D/A
Amendment 1
|
47.9% |
8/3/2026
Event 7/30/2026
|
|
| Catalyst4, Inc. | 47.9% | ||
| Robert Brown | 47.9% | ||
| Ekemini Riley | 47.9% | ||
| Mark Vorsatz | 47.9% | ||
| Novo Holdings A/S 13D/A Amendment 1 | 4.9% |
7/31/2026
Event 7/30/2026
|
|
| T. Rowe Price Investment Management, Inc. 13G/A Amendment 1 | 7.4% |
5/15/2026
Event 3/31/2026
|
|
| T. Rowe Price Investment Management, Inc. 13G | 6.2% |
2/17/2026
Event 12/31/2025
|
|
|
Forbion Growth Opportunities Fund III Cooperatief U.A.
13G
|
7.1% |
2/17/2026
Event 12/31/2025
|
|
| Forbion Growth Opportunities Fund III Cooperatief U.A. | 7.1% | ||
| Forbion Growth III Management B.V. | 7.1% | ||
|
Catalyst4, Inc.
13D
|
45.1% |
11/20/2025
Event 10/28/2025
|
|
| Catalyst4, Inc. | 45.1% | ||
| Robert Brown | 45.1% | ||
| Ekemini Riley | 45.1% | ||
| Mark Vorsatz | 45.1% | ||
| Novo Holdings A/S 13D | 8.4% |
11/4/2025
Event 10/28/2025
|